Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 7/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGAV | P06756 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL4911274 | 0.84 | NISCH (0.44) | NISCHGAATSHR | |
| Hydrochloric Acid SCHEMBL4907533 | 0.77 | NISCH (0.45) | NISCHADRA2AADRA2BADRA2CGAA | |
| Formic Acid SCHEMBL4911292 | 0.74 | SMN1; SMN2 (0.36) | NISCHADRA2AADRA2BADRA2CGAA | |
| Hydrochloric Acid SCHEMBL4910388 | 0.74 | NISCH (0.46) | NISCHADRA2AADRA2BADRA2CGAA | |
| Formic Acid SCHEMBL4911283 | 0.68 | NISCH (0.43) | NISCH | |
| Formic Acid SCHEMBL4912608 | 0.67 | NISCH (0.51) | NISCHADRA2AADRA2BADRA2CGAA | |
| Formic Acid SCHEMBL4813959 | 0.67 | NISCH (0.51) | NISCHGAATSHR | |
| SCHEMBL4362117 | 0.67 | SMN1; SMN2 (0.40) | NISCHADRA2AADRA2BADRA2CGAA | |
| Formic Acid SCHEMBL4912238 | 0.64 | RUVBL1 (0.43) | NISCHGAATSHRITGB3ITGAV | |
| SCHEMBL4362775 | 0.63 | NISCH (0.43) | NISCHGAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MC4R, MC5R, MC3R | NISCH 1934/4885ADRA2A 315/4885ADRA2B 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.